ImmunoGen (IMGN) Financial Analysis & Valuation | Quarter Chart
ImmunoGen (IMGN)
IMGNPrice: $31.23
Fair Value: 🔒
🔒score
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of ... more
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) ther... more
Description
Shares
| Market Cap | $8.73B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mark Joseph Enyedy |
| IPO Date | 1989-11-17 | CAGR | 0.16% |
| Employees | 277 | Website | www.immunogen.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IMGN chart loading...
Fundamentals
Technicals
| Enterprise Value | $3.80B | P/E Ratio | -111.55 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 80.21 | P/B Ratio | 50.84 |
| P/CF Ratio | -34.47 | P/FCF Ratio | -37.75 |
| EPS | $-0.28 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 200.83% | Gross Margin | 1% |
| Operating Margin | -2.03% | Profit Margin | -2.05% |
| ROE | -0.93% | ROA | -0.64% |
| ROCE | -0.97% | Current Ratio | 2.26 |
| Quick Ratio | 2.5 | Cash Ratio | 2.26 |
| Debt/Equity | 0.1 | Interest Coverage | -53.04 |
| Altman Z Score | 18.14 | Piotroski Score | 3 |